The Journal of Practical Medicine ›› 2025, Vol. 41 ›› Issue (18): 2890-2897.doi: 10.3969/j.issn.1006-5725.2025.18.016
• Clinical Research • Previous Articles
Jian ZHAO1,Min DAI1,Ran SUN1,Yajun XU2
Received:
2025-05-23
Online:
2025-09-20
Published:
2025-09-25
CLC Number:
Jian ZHAO,Min DAI,Ran SUN,Yajun XU. Analysis of the relationship between Hp infection and the expression of p27, CyclinD1, MMP⁃9 proteins and the related microRNAs and clinicpathological features in gastric cancer[J]. The Journal of Practical Medicine, 2025, 41(18): 2890-2897.
Tab.2
Expression of p27, CyclinD1, MMP-9 protein and miR-490-3p, miR-146a in cancer tissues and paracancer tissues of GC patients"
项目 | 癌旁组织(n = 116) | 癌组织(n = 116) | t值 | P值 |
---|---|---|---|---|
p27 | 0.34 ± 0.06 | 0.25 ± 0.01 | 15.936 | < 0.001 |
CyclinD1 | 0.45 ± 0.07 | 0.77 ± 0.10 | 28.235 | < 0.001 |
MMP-9 | 0.63 ± 0.09 | 0.95 ± 0.13 | 21.798 | < 0.001 |
miR-490-3p | 1.23 ± 0.22 | 0.53 ± 0.13 | 29.503 | < 0.001 |
miR-146a | 0.40 ± 0.09 | 0.55 ± 0.12 | 10.770 | < 0.001 |
Tab.3
Relationship between Hp infection and expression of p27, CyclinD1, MMP-9 proteins and miR-490-3p, miR-146a in cancer tissues of GC patients"
因素 | Hp阴性组(n = 40) | Hp阳性组(n = 76) | t值 | P值 |
---|---|---|---|---|
p27 | 0.28 ± 0.05 | 0.23 ± 0.03 | 6.728 | < 0.001 |
CyclinD1 | 0.70 ± 0.16 | 0.81 ± 0.12 | 4.171 | < 0.001 |
MMP-9 | 0.86 ± 0.11 | 0.99 ± 0.16 | 4.594 | < 0.001 |
miR-490-3p | 0.62 ± 0.12 | 0.48 ± 0.10 | 6.682 | < 0.001 |
miR-146a | 0.50 ± 0.09 | 0.58 ± 0.11 | 3.953 | < 0.001 |
Tab.4
Relationship between the expression of p27, CyclinD1, MMP-9 protein and miR-490-3p, miR-146a and clinicopathological features in cancer tissues of patients with Hp-positive GC"
因素 | 例数 | p27 | CyclinD1 | MMP-9 | miR-490-3p | miR-146a |
---|---|---|---|---|---|---|
病理学分类 | ||||||
乳头状腺癌 | 29 | 0.23 ± 0.04 | 0.82 ± 0.12 | 1.00 ± 0.15 | 0.48 ± 0.12 | 0.59 ± 0.13 |
管状腺癌 | 27 | 0.22 ± 0.03 | 0.80 ± 0.13 | 0.99 ± 0.18 | 0.49 ± 0.10 | 0.58 ± 0.15 |
腺鳞癌 | 12 | 0.24 ± 0.05 | 0.81 ± 0.15 | 0.98 ± 0.17 | 0.50 ± 0.13 | 0.57 ± 0.11 |
鳞癌 | 8 | 0.24 ± 0.03 | 0.78 ± 0.12 | 0.99 ± 0.15 | 0.46 ± 0.11 | 0.56 ± 0.12 |
肿瘤大小 | ||||||
< 3 cm | 40 | 0.24 ± 0.06 | 0.80 ± 0.15 | 0.99 ± 0.20 | 0.49 ± 0.12 | 0.57 ± 0.14 |
≥ 3 cm | 36 | 0.22 ± 0.04 | 0.82 ± 0.18 | 0.99 ± 0.19 | 0.47 ± 0.16 | 0.59 ± 0.17 |
分化程度 | ||||||
未、低分化 | 38 | 0.22 ± 0.07 | 0.81 ± 0.14 | 1.00 ± 0.13 | 0.46 ± 0.15 | 0.60 ± 0.15 |
中、高分化 | 38 | 0.24 ± 0.06 | 0.80 ± 0.16 | 0.99 ± 0.12 | 0.50 ± 0.13 | 0.56 ± 0.14 |
TNM分期 | ||||||
Ⅰ ~ Ⅱ期 | 38 | 0.25 ± 0.07 | 0.78 ± 0.10 | 0.92 ± 0.11 | 0.53 ± 0.10 | 0.54 ± 0.10 |
Ⅲ ~ Ⅳ期 | 38 | 0.20 ± 0.05* | 0.83 ± 0.06* | 1.06 ± 0.10* | 0.42 ± 0.12* | 0.62 ± 0.11* |
肿瘤浸润深度 | ||||||
肌层以内 | 45 | 0.22 ± 0.10 | 0.82 ± 0.14 | 1.00 ± 0.13 | 0.47 ± 0.12 | 0.59 ± 0.14 |
肌层以外 | 31 | 0.24 ± 0.08 | 0.80 ± 0.15 | 0.98 ± 0.11 | 0.49 ± 0.11 | 0.57 ± 0.16 |
淋巴结转移 | ||||||
有 | 43 | 0.20 ± 0.04# | 0.84 ± 0.12# | 1.02 ± 0.11# | 0.42 ± 0.11# | 0.61 ± 0.08# |
无 | 33 | 0.26 ± 0.07 | 0.77 ± 0.13 | 0.95 ± 0.13 | 0.56 ± 0.11 | 0.55 ± 0.10 |
Tab.5
Expression of p27, CyclinD1, MMP-9 protein and miR-490-3p, miR-146a and clinicopathological characteristics of"
因素 | 例数 | 良好预后组(n = 56) | 不良预后组(n = 20) | χ2/t值 | P值 |
---|---|---|---|---|---|
病理学分类 | 3.000 | 0.730 | |||
乳头状腺癌 | 29 | 23(41.07) | 6(30.00) | ||
管状腺癌 | 27 | 20(35.71) | 7(35.00) | ||
腺鳞癌 | 12 | 8(14.29) | 4(20.00) | ||
鳞癌 | 8 | 5(8.93) | 3(15.00) | ||
肿瘤大小 | 1.737 | 0.188 | |||
< 3 cm | 40 | 32(57.14) | 8(40.00) | ||
≥ 3 cm | 36 | 24(37.50) | 12(60.00) | ||
分化程度 | 2.443 | 0.118 | |||
未、低分化 | 38 | 25(44.64) | 13(65.00) | ||
中、高分化 | 38 | 31(55.36) | 7(35.00) | ||
TNM分期 | 4.343 | 0.037 | |||
Ⅰ ~ Ⅱ期 | 38 | 32(57.14) | 6(30.00) | ||
Ⅲ ~ Ⅳ期 | 38 | 24(42.86) | 14(70.00) | ||
肿瘤浸润深度 | 2.269 | 0.132 | |||
肌层以内 | 45 | 36(64.29) | 9(45.00) | ||
肌层以外 | 31 | 20(35.71) | 11(55.00) | ||
淋巴结转移 | 6.061 | 0.014 | |||
有 | 43 | 27(48.21) | 16(80.00) | ||
无 | 33 | 29(51.79) | 4(20.00) | ||
p27蛋白表达(x ± s) | 0.24 ± 0.04 | 0.20 ± 0.03 | 4.075 | < 0.001 | |
CyclinD1蛋白表达(x ± s) | 0.76 ± 0.11 | 0.95 ±0.13 | 6.317 | < 0.001 | |
MMP-9蛋白表达(x ± s) | 0.95 ± 0.14 | 1.10 ± 0.22 | 3.505 | 0.001 | |
miR-490-3p表达(x ± s) | 0.51 ± 0.03 | 0.38 ± 0.07 | 11.368 | < 0.001 | |
miR-146a表达(x ± s) | 0.55 ± 0.07 | 0.67 ± 0.10 | 5.846 | < 0.001 |
Tab.7
Analysis of risk factors for the occurrence of poor prognosis of Hp-positive GC"
影响因素 | β | SE | Wald χ2 | P值 | OR | 95%CI |
---|---|---|---|---|---|---|
Ⅲ ~ Ⅳ期 | 0.774 | 0.349 | 4.918 | 0.027 | 2.168 | 1.094 ~ 4.298 |
淋巴结有转移 | 0.867 | 0.604 | 2.060 | 0.151 | 2.380 | 0.728 ~ 7.774 |
p27蛋白低表达 | 0.333 | 0.125 | 7.097 | 0.008 | 1.395 | 1.092 ~ 1.782 |
CyclinD1蛋白高表达 | 0.468 | 0.295 | 2.517 | 0.113 | 1.597 | 0.896 ~ 2.847 |
MMP-9蛋白高表达 | 1.064 | 0.412 | 6.669 | 0.010 | 2.898 | 1.292 ~ 6.498 |
miR-490-3p低表达 | 0.608 | 0.300 | 4.107 | 0.043 | 1.837 | 1.020 ~ 3.307 |
miR-146a高表达 | 1.042 | 0.561 | 3.450 | 0.063 | 2.835 | 0.944 ~ 8.513 |
[1] | 王丹萍, 蔡煜锋, 胡德华, 等. LncRNA RMST在胃癌组织中的表达及与诊断和预后的关系[J]. 实用医学杂志, 2025, 41(3): 409-413. |
[2] |
NAVASHENAQ J G, SHABGAH A G, BANACH M, et al. The interaction of Helicobacter pylori with cancer immunomodulatory stromal cells: New insight into gastric cancer pathogenesis[J]. Semin Cancer Biol, 2022, 86(3): 951-959. doi:10.1016/j.semcancer.2021.09.014
doi: 10.1016/j.semcancer.2021.09.014 |
[3] |
LIATSOS C, PAPAEFTHYMIOU A, KYRIAKOS N, et al. Helicobacter pylori, gastric microbiota and gastric cancer relationship: Unrolling the tangle[J]. World J Gastrointest Oncol, 2022, 14(5): 959-972. doi:10.4251/wjgo.v14.i5.959
doi: 10.4251/wjgo.v14.i5.959 |
[4] |
RAZAVIPOUR S F, HARIKUMAR K B, SLINGERLAND J M. p27 as a transcriptional regulator: New roles in development and cancer[J]. Cancer Res, 2020, 80(17): 3451-3458. doi:10.1158/0008-5472.can-19-3663
doi: 10.1158/0008-5472.can-19-3663 |
[5] |
MONTALTO F I, DE AMICIS F. Cyclin D1 in cancer: A molecular connection for cell cycle control, adhesion and invasion in tumor and stroma[J]. Cells, 2020, 9(12): 2648. doi:10.3390/cells9122648
doi: 10.3390/cells9122648 |
[6] |
LU S, ZHANG Z, CHEN M, et al. Erratum: [Corrigendum] silibinin inhibits the migration and invasion of human gastric cancer sgc7901 cells by downregulating mmp-2 and mmp-9 expression via the p38mapk signaling pathway[J]. Oncol Lett, 2024, 29(1): 7. doi:10.3892/ol.2024.14753
doi: 10.3892/ol.2024.14753 |
[7] | 王君君, 王旌, 施源, 等. PCBP2调节miR-490-3p/Rab1A轴对膀胱癌细胞增殖、凋亡和阿霉素耐药性的影响[J]. 中国老年学杂志, 2024, 44(24): 6081-6085. |
[8] |
XIN Q, SHAN S, DING E, et al. Association of microrna polymorphisms with gastric cancer risk in the north chinese han population[J]. J Cancer Res Ther, 2022, 18(2): 581-586. doi:10.4103/jcrt.jcrt_74_21
doi: 10.4103/jcrt.jcrt_74_21 |
[9] | 颜艳, 王彤. 医学统计学[M]. 5版. 北京: 人民卫生出版社, 2020: 252-254. |
[10] | 中华人民共和国国家卫生健康委员会医政医管局. 胃癌诊疗指南(2022年版)[J]. 中华消化外科杂志, 2022, 21(9): 1137-1164. |
[11] | 陈刚. 幽门螺杆菌感染家庭聚集性调查及13C尿素呼气试验中柠檬酸试验餐作用的探索性研究[D]. 合肥: 安徽医科大学, 2024. |
[12] | 周震, 叶冠男, 彭进, 等. Wnt3、β-catenin、MMP-7在胃癌和癌前病变中的表达及其与幽门螺杆菌感染的相关性[J]. 中南大学学报(医学版), 2021, 46(6): 575-582. |
[13] |
YANG H C, FU C F, QIAO L J, et al. Relationship between helicobacter pylori infection and programmed death-ligand 1 in gastric cancer: A meta-analysis[J]. World J Clin Oncol, 2025, 16(4): 102397. doi:10.5306/wjco.v16.i4.102397
doi: 10.5306/wjco.v16.i4.102397 |
[14] | PRATHIPAA R, PRIYATHERSINI N, THANKA J. Expression of matrix metalloproteinase-9 in gastric cancer[J]. Cureus, 2021, 13(9): e18195. |
[15] |
KUMARI S, KUMAR P, KUMAR M, et al. Expression of p27 and p16 and their clinical significance in gastric cancer[J]. Clin Transl Oncol, 2021, 23(4): 856-865. doi:10.1007/s12094-020-02479-4
doi: 10.1007/s12094-020-02479-4 |
[16] |
FENG H, ZHANG H, YAN Z. Clinicopathological significance and prognostic value of P27 expression in gastric cancer patients: A meta-analysis[J]. Anticancer Drugs, 2022, 33(1): 692-699. doi:10.1097/cad.0000000000001240
doi: 10.1097/cad.0000000000001240 |
[17] | 陶嵩. miR-490-3p在胃癌中的表达及其与临床病理特征和预后的关系[D]. 蚌埠: 蚌埠医学院, 2023. |
[18] | 高雅楠. LncRNA MALAT1通过靶向miR-146a调节PI3K/Akt信号通路影响胃癌细胞的增殖、迁移和侵袭[D]. 呼和浩特: 内蒙古医科大学, 2023. |
[19] | 蔡雪华, 杜净红, 王育斌, 等. 幽门螺杆菌阳性胃病患者TGF-β1和miR-146a的表达及意义[J]. 中华医院感染学杂志, 2021, 31(9): 1287-1291. |
[20] |
AL-SHEBOUL S A, MOHAMMAD A A, SHBOUL Y, et al. A genetic and immunohistochemical analysis of helicobacter pylori phenotypes and p27 expression in adenocarcinoma patients in jordan[J]. J Epidemiol Glob Health, 2023, 13(2): 212-225. doi:10.1007/s44197-023-00099-z
doi: 10.1007/s44197-023-00099-z |
[21] |
HA J L, KASER E, GUAN T, et al. Up and away with cervical cancer: Il-29 is a promising cytokine for immunotherapy of cervical cancer due to its powerful upregulation of p18, p27, and trailr1[J]. Med Oncol, 2024, 41(3): 65. doi:10.1007/s12032-023-02276-3
doi: 10.1007/s12032-023-02276-3 |
[22] |
YANAN Z, JUAN W, JUN W, et al. Application of serum gastric function markers and digestive tumor indices to the diagnosis of early gastric cancer and precancerous lesions[J]. Saudi Med J, 2023, 44(8): 795-800. doi:10.15537/smj.2023.44.8.20230231
doi: 10.15537/smj.2023.44.8.20230231 |
[23] |
LI Y, TIAN D, CHEN H, et al. Microrna-490-3p and -490-5p in carcinogenesis: Separate or the same goal?[J] Oncol Lett, 2021, 22(3): 678. doi:10.3892/ol.2021.12939
doi: 10.3892/ol.2021.12939 |
[24] |
ZHAN T, CHEN M, LIU W, et al. Mir-455-3p inhibits gastric cancer progression by repressing wnt/beta-catenin signaling through binding to armc8[J]. BMC Med Genomics, 2023, 16(1): 155. doi:10.1186/s12920-023-01583-y
doi: 10.1186/s12920-023-01583-y |
[25] |
HUANG Y, CHEN M, JIANG F, et al. Microfluidic-sers sensing system based on dual signal amplification and aptamer for gastric cancer detection[J]. Mikrochim Acta, 2024, 191(11): 668. doi:10.1007/s00604-024-06760-z
doi: 10.1007/s00604-024-06760-z |
[26] |
KARIMI M, MOHAMMADNIA A, AMINI M A, et al. Overexpression of mir-146a and mir-155 are potentially biomarkers and predict unfavorable relationship between gastric cancer and helicobacter pylori infection[J]. Chonnam Med J, 2023, 59(3): 167-173. doi:10.4068/cmj.2023.59.3.167
doi: 10.4068/cmj.2023.59.3.167 |
[27] |
LIU C, GAO W, SHI Y, et al. Association between mir-146a rs2910164, mir-196a2 rs11614913, and mir-499 rs3746444 polymorphisms and the risk of esophageal carcinoma: A case-control study[J]. Cancer Med, 2022, 11(21): 3949-3959. doi:10.1002/cam4.4729
doi: 10.1002/cam4.4729 |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||